TINA SOO: Open Payments
NPI 1447494679 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,029 in 35 payments from 17 companies in 2025. Trend: 2023 $650 · 2024 $1,134 · 2025 $1,029
Food & beverage: $960Education: $68
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $284 |
| Eisai Inc. | 6 | $168 |
| Syndax Pharmaceuticals, Inc. | 1 | $103 |
| GENZYME CORPORATION | 2 | $69 |
| JAZZ PHARMACEUTICALS INC. | 1 | $63 |
| Daiichi Sankyo Inc. | 2 | $51 |
| BeOne Medicines USA, Inc. | 2 | $48 |
| SOBI, INC | 1 | $43 |
| Incyte Corporation | 1 | $28 |
| E.R. Squibb & Sons, L.L.C. | 1 | $26 |
Products named: CALQUENCE, Lenvima, SARCLISA, IMFINZI, BRUKINSA, ZIIHERA, DATROWAY, Doptelet.
Industry payments across CA — which companies pay providers there.
